Episode 12 – PML: what is it, and why is it relevant in MS?
01 września 2025
In the final episode of the Illuminoz podcast series, Bianca Stadler speaks with Dr. Tobias Bopp – immunologist and director of the Institute of Immunology in Mainz – about the risk of progressive multifocal leukoencephalopathy (PML) in MS treatment and the role of JC virus testing.
What immune mechanisms protect against PML? What are the key risk factors when using natalizumab? And how does JCV antibody testing support safer treatment decisions?
This episode highlights the importance of safety, biomarkers, and personalized care in the evolving landscape of MS therapy.
Informacje o podcaście:
“Illuminoz talks 2025” podcast series:
Episode 11 – Introducing biosimilar natalizumab
dr Heinz Wiendl,
Episode 10 – Patient conversations part three: the patient perspective
Ellen Tutton,
Episode 9 – Patient conversations part two: the nurse perspective
karolinamalicka,
Episode 8 – Patient conversations part one: the neurologist perspective
dr Agne Straukiene,
Episode 7 – Lessons learned part two: the value of biosimilars in rheumatology
prof. Paul Emery,
Episode 6 – Lessons learned part one: the value of biosimilars in oncology
prof. Kai Hübel,
Episode 5 – Biosimilars and MS: improving access to high-efficacy treatment
dr Barbara Kornek,
Episode 4 – Treatment paradigms in MS: right patient, right treatment, right time
dr Laura Airas,
Episode 3 – MS treatment landscape part two: potential role of biosimilars
dr David Paling,
Episode 2 – MS treatment landscape part one: unmet needs
dr Luisa Klotz,
Episode 1 – Biosimilars: what are they, and why might they be important for MS?
dr Wallace Brownlee,
